US patent granted for Aussie biotech’s unique binding systems
A key US patent for Prescient Therapeutics’ OmniCAR platform has been granted, the Australian biotech company has announced, ensuring protection...
News
Immunotherapy
News
Prescient unveils new platform after 18 months in stealth mode
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with...
News
Prescient Therapeutics expands PTX-200 testing after fourth complete remission
Australian biotechnology company Prescient Therapeutics will expand testing of its PTX-200 drug after another patient suffering a deadly blood cancer,...
News
Prescient in strong financial position after productive quarter
Australian biotech company Prescient Therapeutics has ended the March quarter with a sizeable cash balance despite continued investment into research...
News
‘Exciting clinical and commercial opportunity’: Prescient
Australian biotechnology company Prescient Therapeutics is enrolling up to 12 new patients for the next round of trials on its...
News
Milestones struck as Prescient due to emerge from ‘stealth mode’ on new tech
Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in the first half of the...
News
Cancer therapy pioneer uses the word ‘cure’ after CAR-T breakthrough
A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy has shown such promising results...
News
Investors ‘beginning to appreciate’ scale of biotech market opportunity
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and investors are taking notice, says...
News
US drug administration signals further support for CAR-T cancer treatments
The US Food and Drug Administration has assigned a fast track designation to a new CAR-T cancer treatment for multiple...
News
Prescient Therapeutics delivers positive immune response test results
Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing demonstrated the company’s OmniCAR binding...